Novartis divests part of Sandoz US Genercis as well as US dermatology business to Aurobindo Pharma for $0.9B

Novartis divests part of Sandoz US Genercis as well as US dermatology business to Aurobindo Pharma for $0.9B

Novartis divests part of Sandoz US Genercis as well as US dermatology business to Aurobindo Pharma for $0.9B

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © 2020 Digiqole. All Right Reserved.